Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase
Xiaoyong Fu(King University), Rachel Schiff(Baylor College of Medicine), Martin J. Shea(Baylor College of Medicine), Vijetha Kumar(Baylor College of Medicine), Carolina Gutiérrez(Baylor College of Medicine), Sabrina Herrera(Mayo Clinic), Alejandro Contreras(Baylor College of Medicine), Joe W. Gray(University of Newcastle Australia), C. Kent Osborne(Texas Oncology), Paul D. Smith(Epworth Hospital), Kristen L. Karlin(Baylor College of Medicine), Sylvie M. Guichard(Novo Nordisk (United Kingdom)), Thomas F. Westbrook(Baylor College of Medicine), Adrian V. Lee(Baylor College of Medicine), Paul T. Spellman(Oregon Health & Science University), Pavana Anur, Gladys Morrison(Baylor College of Medicine), Chad J. Creighton(Baylor College of Medicine), Agostina Nardone(AstraZeneca (Spain)), Teresa Klinowska(AstraZeneca (Singapore)), Mario Giuliano(Regione Campania), Nrusingh C. Biswal(Baylor College of Medicine), Sarmistha Nanda(Baylor College of Medicine), Mothaffar F. Rimawi(Baylor College of Medicine), Susan G. Hilsenbeck(Baylor College of Medicine), Amit Joshi(Baylor College of Medicine), Laura M. Heiser(Oregon Health & Science University), Barry R. Davies(Immodulon Therapeutics (United Kingdom)), Tao Wang(Pfizer (United States)), Gordon B. Mills(The University of Texas MD Anderson Cancer Center)
Cited by 70
Related Papers
UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses
|Neoplasia|2017|6.5k
UALCAN: An update to the integrated cancer data analysis platform
|Neoplasia|2022|2.5k
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k